Repligen Corp (RGEN) Dividend History

Company News

• Repligen's Q4 Slightly Tops Expectations

  Repligen, a bioprocessing technology company, reported mixed Q4 results. While adjusted EPS exceeded expectations, GAAP gross margin declined significantly due to restructuring and other costs. The company is focused on product innovations and strategic acquisitions to drive growth.

  The Motley Fool
• Chromatography System Market to Reach US$ 2.62 Billion with 6.6% CAGR by 2034 | Fact.MR Report

  The global chromatography system market is expected to grow at a CAGR of 6.6% from 2024 to 2034, driven by increasing applications in the biotechnology sector and technological advancements that simplify procedures and reduce human error.

  GlobeNewswire Inc.

  Featured Companies: A BIO BIO.B BRKR TMO WAT
• BioLife Solutions Appoints Tony J. Hunt to its Board of Directors

  BioLife Solutions, a leading developer and supplier of bioproduction tools and services for the cell and gene therapy market, has appointed Tony J. Hunt, Executive Chairman of Repligen Corporation, to its board of directors. Hunt's appointment is expected to strengthen BioLife's focus on extending its position as a provider of industry-leading solutions for bioproduction workflows in the cell and gene therapy market.

  Benzinga

  Featured Companies: BLFS
• Repligen (RGEN) Soars 4.4%: Is Further Upside Left in the Stock?

  Repligen (RGEN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

  Zacks Investment Research

  Featured Companies: ANAB
• Unloved Gilead Due For Reversal On Flight-To-Safety Money Flows

  Numerous drugs under development are projected to come to market later this year and next for Gilead. Read why I rate GILD stock a Buy.

  Seeking Alpha

  Featured Companies: ABBV AMGN BIIB BMY GILD LLY MRK PFE VRTX XPH